{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:18:14Z","timestamp":1792113494818,"version":"4.4.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40263-025-01159-7","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T07:37:27Z","timestamp":1739605047000},"page":"361-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9562-4984","authenticated-orcid":false,"given":"Alyssa A.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-0352","authenticated-orcid":false,"given":"Rudri","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-1018","authenticated-orcid":false,"given":"Tanvi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-2290","authenticated-orcid":false,"given":"Robert W.","family":"Motl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"issue":"10","key":"1159_CR1","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029\u201340.","journal-title":"Neurology"},{"issue":"6","key":"1159_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/14737175.2018.1478289","volume":"18","author":"JF Baird","year":"2018","unstructured":"Baird JF, Sandroff BM, Motl RW. Therapies for mobility disability in persons with multiple sclerosis. Expert Rev Neurother. 2018;18(6):493\u2013502.","journal-title":"Expert Rev Neurother"},{"key":"1159_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","volume":"4","author":"NG LaRocca","year":"2011","unstructured":"LaRocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4:189\u2013201.","journal-title":"Patient"},{"issue":"4","key":"1159_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/JNN.0b013e3181e26c5f","volume":"42","author":"RW Motl","year":"2010","unstructured":"Motl RW, McAuley E. Symptom cluster and quality of life: preliminary evidence in multiple sclerosis. J Neurosci Nurs. 2010;42(4):212\u20136.","journal-title":"J Neurosci Nurs"},{"issue":"1\u20132","key":"1159_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jns.2013.02.021","volume":"328","author":"BM Sandroff","year":"2013","unstructured":"Sandroff BM, Sosnoff JJ, Motl RW. Physical fitness, walking performance, and gait in multiple sclerosis. J Neurol Sci. 2013;328(1\u20132):70\u20136.","journal-title":"J Neurol Sci"},{"issue":"17","key":"1159_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):789\u2013800.","journal-title":"Neurology"},{"issue":"10","key":"1159_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/qjmed\/hch105","volume":"97","author":"L Hemmett","year":"2004","unstructured":"Hemmett L, et al. What drives quality of life in multiple sclerosis? QJM. 2004;97(10):671\u20136.","journal-title":"QJM"},{"issue":"5","key":"1159_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","volume":"65","author":"DL Vargas","year":"2017","unstructured":"Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017;65(5):883\u201391.","journal-title":"J Investig Med"},{"key":"1159_CR9","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. In: Mayo Clinic Proceedings. Elsevier; 2014.","DOI":"10.1016\/j.mayocp.2013.11.002"},{"issue":"1","key":"1159_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7224\/1537-2073-2.1.51","volume":"2","author":"A Chan","year":"2000","unstructured":"Chan A, Heck C. Mobility in multiple sclerosis: more than just a physical problem. Int J MS Care. 2000;2(1):51\u201361.","journal-title":"Int J MS Care"},{"key":"1159_CR11","doi-asserted-by":"publisher","first-page":"175628642110667","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, et al. Smouldering multiple sclerosis: the \u2018real MS.\u2019 Ther Adv Neurol Diso. 2022;15:17562864211066752.","journal-title":"Ther Adv Neurol Diso"},{"issue":"6","key":"1159_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","volume":"13","author":"RA Marrie","year":"2017","unstructured":"Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13(6):375\u201382.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1159_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.pmr.2012.11.004","volume":"24","author":"RW Motl","year":"2013","unstructured":"Motl RW. Ambulation and multiple sclerosis. Phys Med Rehabil Clin. 2013;24(2):325\u201336.","journal-title":"Phys Med Rehabil Clin"},{"issue":"12","key":"1159_CR14","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.apmr.2013.07.011","volume":"94","author":"RE Klaren","year":"2013","unstructured":"Klaren RE, et al. Objectively quantified physical activity in persons with multiple sclerosis. Arch Phys Med Rehabil. 2013;94(12):2342\u20138.","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"1159_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/JES.0b013e3181f44fab","volume":"38","author":"RW Motl","year":"2010","unstructured":"Motl RW. Physical activity and irreversible disability in multiple sclerosis. Exerc Sport Sci Rev. 2010;38(4):186\u201391.","journal-title":"Exerc Sport Sci Rev"},{"key":"1159_CR16","doi-asserted-by":"crossref","unstructured":"Abou L, et al. A nationwide update on prevalence of falls, injurious falls, concerns about falling, and fall prevention in persons with multiple sclerosis. Am J Phys Med Rehabil. 2024;103(9):811\u2013918.","DOI":"10.1097\/PHM.0000000000002454"},{"issue":"11","key":"1159_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028021","volume":"6","author":"JJ Sosnoff","year":"2011","unstructured":"Sosnoff JJ, et al. Mobility, balance and falls in persons with multiple sclerosis. PLoS ONE. 2011;6(11): e28021.","journal-title":"PLoS ONE"},{"issue":"6","key":"1159_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1586\/14737175.2015.1046377","volume":"15","author":"JJ Sosnoff","year":"2015","unstructured":"Sosnoff JJ, Sung J. Reducing falls and improving mobility in multiple sclerosis. Expert Rev Neurother. 2015;15(6):655\u201366.","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"1159_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1474-4422(05)70193-9","volume":"4","author":"J Kesselring","year":"2005","unstructured":"Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005;4(10):643\u201352.","journal-title":"Lancet Neurol"},{"key":"1159_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/B978-0-444-52001-2.00023-6","volume":"122","author":"A Toosy","year":"2014","unstructured":"Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol. 2014;122:513\u201362.","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"1159_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s10072-023-06795-9","volume":"44","author":"S Ghorbanpour","year":"2023","unstructured":"Ghorbanpour S, et al. Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurol Sci. 2023;44(9):3059\u201369.","journal-title":"Neurol Sci"},{"issue":"5","key":"1159_CR22","first-page":"S146","volume":"17","author":"JR Berger","year":"2011","unstructured":"Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(5):S146.","journal-title":"Am J Manag Care"},{"issue":"2","key":"1159_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/1756285611430719","volume":"5","author":"U Dalgas","year":"2012","unstructured":"Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? Ther Adv Neurol Diso. 2012;5(2):81\u201395.","journal-title":"Ther Adv Neurol Diso"},{"issue":"2","key":"1159_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1474-4422(14)70231-5","volume":"14","author":"A Feinstein","year":"2015","unstructured":"Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14(2):194\u2013207.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1159_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.7224\/1537-2073.2016-062","volume":"19","author":"SD Newsome","year":"2017","unstructured":"Newsome SD, et al. A framework of care in multiple sclerosis, part 2: symptomatic care and beyond. Int J MS Care. 2017;19(1):42\u201356.","journal-title":"Int J MS Care"},{"key":"1159_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.msard.2018.01.021","volume":"20","author":"S Charron","year":"2018","unstructured":"Charron S, McKay KA, Tremlett H. Physical activity and disability outcomes in multiple sclerosis: a systematic review (2011\u20132016). Mult Scler Relat Diso. 2018;20:169\u201377.","journal-title":"Mult Scler Relat Diso"},{"key":"1159_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.msard.2017.06.003","volume":"16","author":"T Edwards","year":"2017","unstructured":"Edwards T, Pilutti LA. The effect of exercise training in adults with multiple sclerosis with severe mobility disability: a systematic review and future research directions. Mult Scler Relat Diso. 2017;16:31\u20139.","journal-title":"Mult Scler Relat Diso"},{"key":"1159_CR28","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0022-510X(11)70008-9","volume":"311","author":"U Dalgas","year":"2011","unstructured":"Dalgas U. Rehabilitation and multiple sclerosis: hot topics in the preservation of physical functioning. J Neurol Sci. 2011;311:S43\u20137.","journal-title":"J Neurol Sci"},{"key":"1159_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fresc.2021.795306","volume":"2","author":"P Plummer","year":"2022","unstructured":"Plummer P, Markovic-Plese S, Giesser B. Dalfampridine for mobility limitations in people with multiple sclerosis may be augmented by physical therapy: a non-randomized two-group proof-of-concept pilot study. Front Rehabil Sci. 2022;2: 795306.","journal-title":"Front Rehabil Sci"},{"key":"1159_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:1\u20137.","journal-title":"BMC Med Res Methodol"},{"key":"1159_CR31","volume-title":"Multiple sclerosis: the history of a disease","author":"TJ Murray","year":"2004","unstructured":"Murray TJ. Multiple sclerosis: the history of a disease. New York: Demos Medical Publishing; 2004."},{"issue":"6","key":"1159_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/014107680509800616","volume":"98","author":"RW Orrell","year":"2005","unstructured":"Orrell RW. Multiple sclerosis: the history of a disease. J R Soc Med. 2005;98(6):289.","journal-title":"J R Soc Med"},{"issue":"5","key":"1159_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/00127893-200209000-00002","volume":"8","author":"O St\u00fcve","year":"2002","unstructured":"St\u00fcve O, et al. Approved and future pharmacotherapy for multiple sclerosis. Neurologist. 2002;8(5):290\u2013301.","journal-title":"Neurologist"},{"issue":"4","key":"1159_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):65\u201394.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1159_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jphys.2019.08.005","volume":"66","author":"AG Cashin","year":"2020","unstructured":"Cashin AG, McAuley JH. Clinimetrics: physiotherapy evidence database (PEDro) scale. J Physiother. 2020;66(1):59.","journal-title":"J Physiother"},{"issue":"9","key":"1159_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222288","volume":"14","author":"J Shi","year":"2019","unstructured":"Shi J, Wu X, Chen Y. Study on dalfampridine in the treatment of multiple sclerosis mobility disability: a meta-analysis. PLoS ONE. 2019;14(9): e0222288.","journal-title":"PLoS ONE"},{"key":"1159_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01694-8","volume":"16","author":"E Zhang","year":"2021","unstructured":"Zhang E, et al. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. Orphanet J Rare Dis. 2021;16:1\u201312.","journal-title":"Orphanet J Rare Dis"},{"key":"1159_CR38","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s40263-019-00671-x","volume":"33","author":"M Valet","year":"2019","unstructured":"Valet M, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33:1087\u201399.","journal-title":"CNS Drugs"},{"issue":"15","key":"1159_CR39","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","volume":"71","author":"A Goodman","year":"2008","unstructured":"Goodman A, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71(15):1134\u201341.","journal-title":"Neurology"},{"issue":"4","key":"1159_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.22240","volume":"68","author":"AD Goodman","year":"2010","unstructured":"Goodman AD, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494\u2013502.","journal-title":"Ann Neurol"},{"issue":"9665","key":"1159_CR41","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732\u20138.","journal-title":"Lancet"},{"issue":"3","key":"1159_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1352458506069538","volume":"13","author":"AD Goodman","year":"2007","unstructured":"Goodman AD, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler J. 2007;13(3):357\u201368.","journal-title":"Mult Scler J"},{"issue":"1","key":"1159_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40263-018-0586-5","volume":"33","author":"J Hobart","year":"2019","unstructured":"Hobart J, et al. Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, Phase III ENHANCE trial of prolonged-release fampridine. CNS Drugs. 2019;33(1):61\u201379.","journal-title":"CNS Drugs"},{"issue":"2","key":"1159_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/1352458515581436","volume":"22","author":"R Hupperts","year":"2016","unstructured":"Hupperts R, et al. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Mult Scler. 2016;22(2):212\u201321.","journal-title":"Mult Scler"},{"key":"1159_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.msard.2016.07.019","volume":"10","author":"HB Jensen","year":"2016","unstructured":"Jensen HB, et al. Effect of slow release-fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study. Mult Scler Relat Disord. 2016;10:137\u201344.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1159_CR46","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s13311-019-00813-5","volume":"17","author":"L Prosperini","year":"2020","unstructured":"Prosperini L, et al. Dalfampridine to improve balance in multiple sclerosis: substudy from a randomized placebo-controlled trial. Neurotherapeutics. 2020;17(2):704\u20139.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1159_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1352458518815795","volume":"26","author":"N Satchidanand","year":"2020","unstructured":"Satchidanand N, et al. Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Mult Scler. 2020;26(1):91\u20138.","journal-title":"Mult Scler"},{"issue":"4","key":"1159_CR48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1212\/WNL.48.4.817","volume":"48","author":"SR Schwid","year":"1997","unstructured":"Schwid SR, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997;48(4):817\u201321.","journal-title":"Neurology"},{"issue":"3","key":"1159_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.7224\/1537-2073.2014-040","volume":"17","author":"R Yapundich","year":"2015","unstructured":"Yapundich R, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: a randomized controlled trial. Int J MS Care. 2015;17(3):138\u201345.","journal-title":"Int J MS Care"},{"issue":"11","key":"1159_CR50","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1177\/1352458515622695","volume":"22","author":"B Z\u00f6rner","year":"2016","unstructured":"Z\u00f6rner B, et al. Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Mult Scler. 2016;22(11):1463\u201375.","journal-title":"Mult Scler"},{"key":"1159_CR51","doi-asserted-by":"publisher","first-page":"105382","DOI":"10.1016\/j.clinbiomech.2021.105382","volume":"86","author":"M Valet","year":"2021","unstructured":"Valet M, et al. Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study. Clin Biomech. 2021;86:105382.","journal-title":"Clin Biomech"},{"issue":"16","key":"1159_CR52","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1212\/WNL.0b013e31828cf7f3","volume":"80","author":"J Hobart","year":"2013","unstructured":"Hobart J, et al. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509\u201317.","journal-title":"Neurology"},{"key":"1159_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103438","volume":"57","author":"DM Oosterveer","year":"2022","unstructured":"Oosterveer DM, et al. Determining the minimal important change of the 6-minute walking test in multiple sclerosis patients using a predictive modelling anchor-based method. Mult Scler Relat Diso. 2022;57: 103438.","journal-title":"Mult Scler Relat Diso"},{"issue":"3","key":"1159_CR54","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/biof.1936","volume":"49","author":"B Abd-Nikfarjam","year":"2023","unstructured":"Abd-Nikfarjam B, et al. Cannabinoids in neuroinflammatory disorders: focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases. BioFactors. 2023;49(3):560\u201383.","journal-title":"BioFactors"},{"issue":"5","key":"1159_CR55","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjp.0707458","volume":"152","author":"D Baker","year":"2007","unstructured":"Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007;152(5):649\u201354.","journal-title":"Br J Pharmacol"},{"key":"1159_CR56","doi-asserted-by":"crossref","unstructured":"Rodrigues RS, et al. Cannabinoid actions on neural stem cells: implications for pathophysiology. Molecules. 2019;24(7):1350.","DOI":"10.3390\/molecules24071350"},{"key":"1159_CR57","doi-asserted-by":"publisher","first-page":"17745","DOI":"10.1038\/srep17745","volume":"5","author":"B Paniagua-Torija","year":"2015","unstructured":"Paniagua-Torija B, et al. CB1 cannabinoid receptor enrichment in the ependymal region of the adult human spinal cord. Sci Rep. 2015;5:17745.","journal-title":"Sci Rep"},{"key":"1159_CR58","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","volume":"168","author":"K Mackie","year":"2005","unstructured":"Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;168:299\u2013325.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"1159_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/15504263.2019.1668100","volume":"16","author":"AL Milligan","year":"2020","unstructured":"Milligan AL, Szabo-Pardi TA, Burton MD. Cannabinoid receptor type 1 and its role as an analgesic: an opioid alternative? J Dual Diagn. 2020;16(1):106\u201319.","journal-title":"J Dual Diagn"},{"issue":"7","key":"1159_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11916-020-00873-9","volume":"24","author":"J Wolf","year":"2020","unstructured":"Wolf J, et al. The role of the cannabinoid system in pain control: basic and clinical implications. Curr Pain Headache Rep. 2020;24(7):35.","journal-title":"Curr Pain Headache Rep"},{"key":"1159_CR61","doi-asserted-by":"crossref","unstructured":"Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.","DOI":"10.3390\/ijms19030833"},{"issue":"2","key":"1159_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.bjp.0707584","volume":"153","author":"GA Cabral","year":"2008","unstructured":"Cabral GA, et al. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008;153(2):240\u201351.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1159_CR63","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825\u201336.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1159_CR64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","volume":"10","author":"C Vaney","year":"2004","unstructured":"Vaney C, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417\u201324.","journal-title":"Mult Scler"},{"issue":"9395","key":"1159_CR65","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","volume":"362","author":"J Zajicek","year":"2003","unstructured":"Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517\u201326.","journal-title":"Lancet"},{"issue":"11","key":"1159_CR66","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/jnnp-2012-302468","volume":"83","author":"JP Zajicek","year":"2012","unstructured":"Zajicek JP, et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1159_CR67","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","volume":"14","author":"C Collin","year":"2007","unstructured":"Collin C, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290\u20136.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1159_CR68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","volume":"32","author":"C Collin","year":"2010","unstructured":"Collin C, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451\u20139.","journal-title":"Neurol Res"},{"issue":"9","key":"1159_CR69","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","volume":"18","author":"A Novotna","year":"2011","unstructured":"Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(\u00ae) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122\u201331.","journal-title":"Eur J Neurol"},{"issue":"6","key":"1159_CR70","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"DJ Rog","year":"2005","unstructured":"Rog DJ, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812\u20139.","journal-title":"Neurology"},{"issue":"4","key":"1159_CR71","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"DT Wade","year":"2004","unstructured":"Wade DT, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434\u201341.","journal-title":"Mult Scler"},{"issue":"10","key":"1159_CR72","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1503\/cmaj.110837","volume":"184","author":"J Corey-Bloom","year":"2012","unstructured":"Corey-Bloom J, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143\u201350.","journal-title":"CMAJ"},{"key":"1159_CR73","doi-asserted-by":"publisher","unstructured":"Bowery NG. Baclofen: therapeutic use and potential of the prototypic GABAB receptor agonist. In: Colombo G (eds) GABAB Receptor. The Receptors, vol 29. Cham: Humana Press; 2016. https:\/\/doi.org\/10.1007\/978-3-319-46044-4_17.","DOI":"10.1007\/978-3-319-46044-4_17"},{"issue":"1","key":"1159_CR74","first-page":"3","volume":"16","author":"MJ McLaughlin","year":"2023","unstructured":"McLaughlin MJ, Fisher MT. A critical evaluation of oral baclofen in pediatric patients with cerebral palsy. J Pediatr Rehabil Med. 2023;16(1):3\u20139.","journal-title":"J Pediatr Rehabil Med"},{"key":"1159_CR75","doi-asserted-by":"crossref","unstructured":"Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix\u2013x, 1\u2013111.","DOI":"10.3310\/hta7400"},{"issue":"5","key":"1159_CR76","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","volume":"10","author":"MA Rizzo","year":"2004","unstructured":"Rizzo MA, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589\u201395.","journal-title":"Mult Scler"},{"issue":"4","key":"1159_CR77","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1034\/j.1600-0404.2000.101004244x.\/","volume":"101","author":"GB Orsnes","year":"2000","unstructured":"Orsnes GB, et al. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand. 2000;101(4):244\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1159_CR78","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jbmt.2020.06.014","volume":"24","author":"M Pau","year":"2020","unstructured":"Pau M, et al. Timed Up and Go in men and women with multiple sclerosis: effect of muscular strength. J Bodyw Mov Ther. 2020;24(4):124\u201330.","journal-title":"J Bodyw Mov Ther"},{"issue":"5","key":"1159_CR79","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/1352458510361357","volume":"16","author":"D Gijbels","year":"2010","unstructured":"Gijbels D, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler. 2010;16(5):618\u201326.","journal-title":"Mult Scler"},{"key":"1159_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/ijtr.2020.0059","volume":"2020","author":"H Karpatkin","year":"2020","unstructured":"Karpatkin H, et al. Pilot trial of speed-intensive gait training on balance and walking in people with multiple sclerosis. Int J Ther Rehabil. 2020;2020:1\u201310.","journal-title":"Int J Ther Rehabil"},{"issue":"1","key":"1159_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40271-013-0028-x","volume":"7","author":"CG Kohn","year":"2014","unstructured":"Kohn CG, et al. Walking speed and health-related quality of life in multiple sclerosis. Patient. 2014;7(1):55\u201361.","journal-title":"Patient"},{"issue":"Suppl 5 Improvi","key":"1159_CR82","first-page":"S139","volume":"17","author":"HL Zwibel","year":"2011","unstructured":"Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5 Improving):S139\u201345.","journal-title":"Am J Manag Care"},{"key":"1159_CR83","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/B978-0-444-63916-5.00015-X","volume":"159","author":"MH Cameron","year":"2018","unstructured":"Cameron MH, Nilsagard Y. Balance, gait, and falls in multiple sclerosis. Handb Clin Neurol. 2018;159:237\u201350.","journal-title":"Handb Clin Neurol"},{"issue":"11","key":"1159_CR84","doi-asserted-by":"publisher","first-page":"815","DOI":"10.5312\/wjo.v8.i11.815","volume":"8","author":"E Yiou","year":"2017","unstructured":"Yiou E, et al. Balance control during gait initiation: State-of-the-art and research perspectives. World J Orthop. 2017;8(11):815\u201328.","journal-title":"World J Orthop"},{"issue":"4","key":"1159_CR85","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/02537176211021280","volume":"43","author":"C Andrade","year":"2021","unstructured":"Andrade C. The ceiling effect, the floor effect, and the importance of active and placebo control arms in randomized controlled trials of an investigational drug. Indian J Psychol Med. 2021;43(4):360\u20131.","journal-title":"Indian J Psychol Med"},{"issue":"3","key":"1159_CR86","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/00273170802285941","volume":"43","author":"L Wang","year":"2009","unstructured":"Wang L, et al. Investigating ceiling effects in longitudinal data analysis. Multivariate Behav Res. 2009;43(3):476\u201396.","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"1159_CR87","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.pmr.2013.07.002","volume":"24","author":"V Stevens","year":"2013","unstructured":"Stevens V, et al. Gait impairment and optimizing mobility in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):573\u201392.","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"2","key":"1159_CR88","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2522\/ptj.20120171","volume":"93","author":"M Godi","year":"2013","unstructured":"Godi M, et al. Comparison of reliability, validity, and responsiveness of the mini-BESTest and Berg Balance Scale in patients with balance disorders. Phys Ther. 2013;93(2):158\u201367.","journal-title":"Phys Ther"},{"key":"1159_CR89","doi-asserted-by":"crossref","unstructured":"Mehta T, et al. Comparing the convergent and concurrent validity of the dynamic gait index with the berg balance scale in people with multiple sclerosis. Healthcare (Basel). 2019;7(1):27.","DOI":"10.3390\/healthcare7010027"},{"issue":"9","key":"1159_CR90","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2522\/ptj.20150416","volume":"96","author":"E Ross","year":"2016","unstructured":"Ross E, et al. Cohort study comparing the Berg Balance Scale and the Mini-BESTest in people who have multiple sclerosis and are ambulatory. Phys Ther. 2016;96(9):1448\u201355.","journal-title":"Phys Ther"},{"issue":"6","key":"1159_CR91","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/apmr.2002.32825","volume":"83","author":"D Cattaneo","year":"2002","unstructured":"Cattaneo D, et al. Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil. 2002;83(6):864\u20137.","journal-title":"Arch Phys Med Rehabil"},{"issue":"9","key":"1159_CR92","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.apmr.2006.06.002","volume":"87","author":"ML Finlayson","year":"2006","unstructured":"Finlayson ML, Peterson EW, Cho CC. Risk factors for falling among people aged 45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil. 2006;87(9):1274\u20139 (quiz 1287).","journal-title":"Arch Phys Med Rehabil"},{"issue":"7","key":"1159_CR93","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.pmrj.2011.04.015","volume":"3","author":"PN Matsuda","year":"2011","unstructured":"Matsuda PN, et al. Falls in multiple sclerosis. PMR. 2011;3(7):624\u201332 (quiz 632).","journal-title":"PMR"},{"issue":"2","key":"1159_CR94","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.gaitpost.2004.01.008","volume":"21","author":"T Bhatt","year":"2005","unstructured":"Bhatt T, Wening JD, Pai YC. Influence of gait speed on stability: recovery from anterior slips and compensatory stepping. Gait Posture. 2005;21(2):146\u201356.","journal-title":"Gait Posture"},{"issue":"3","key":"1159_CR95","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.gaitpost.2010.06.013","volume":"32","author":"DD Espy","year":"2010","unstructured":"Espy DD, et al. Independent influence of gait speed and step length on stability and fall risk. Gait Posture. 2010;32(3):378\u201382.","journal-title":"Gait Posture"},{"issue":"14","key":"1159_CR96","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1177\/1352458513488233","volume":"19","author":"H Gunn","year":"2013","unstructured":"Gunn H, et al. Risk factors for falls in multiple sclerosis: an observational study. Mult Scler. 2013;19(14):1913\u201322.","journal-title":"Mult Scler"},{"issue":"4","key":"1159_CR97","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7224\/1537-2073.2016-049","volume":"19","author":"JE Zelaya","year":"2017","unstructured":"Zelaya JE, Murchison C, Cameron M. Associations between bladder dysfunction and falls in people with relapsing-remitting multiple sclerosis. Int J MS Care. 2017;19(4):184\u201390.","journal-title":"Int J MS Care"},{"key":"1159_CR98","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2017.00538","volume":"8","author":"T Cronin","year":"2017","unstructured":"Cronin T, Arshad Q, Seemungal BM. Vestibular deficits in neurodegenerative disorders: balance, dizziness, and spatial disorientation. Front Neurol. 2017;8:538.","journal-title":"Front Neurol"},{"issue":"9","key":"1159_CR99","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/ncpneuro0886","volume":"4","author":"CG Horlings","year":"2008","unstructured":"Horlings CG, et al. A weak balance: the contribution of muscle weakness to postural instability and falls. Nat Clin Pract Neurol. 2008;4(9):504\u201315.","journal-title":"Nat Clin Pract Neurol"},{"key":"1159_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104838","volume":"76","author":"A Jawad","year":"2023","unstructured":"Jawad A, et al. Factors contributing to falls in people with multiple sclerosis: the exploration of the moderation and mediation effects. Mult Scler Relat Disord. 2023;76: 104838.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1159_CR101","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1191\/0269215505cr839oa","volume":"19","author":"J Kileff","year":"2005","unstructured":"Kileff J, Ashburn A. A pilot study of the effect of aerobic exercise on people with moderate disability multiple sclerosis. Clin Rehabil. 2005;19(2):165\u20139.","journal-title":"Clin Rehabil"},{"issue":"2","key":"1159_CR102","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1545968308320641","volume":"23","author":"EM Snook","year":"2009","unstructured":"Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair. 2009;23(2):108\u201316.","journal-title":"Neurorehabil Neural Repair"},{"issue":"2","key":"1159_CR103","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1123\/jsr.16.2.143","volume":"16","author":"C Ay\u00e1n P\u00e9rez","year":"2007","unstructured":"Ay\u00e1n P\u00e9rez C, et al. Effects of a resistance training program in multiple sclerosis Spanish patients: a pilot study. J Sport Rehabil. 2007;16(2):143\u201353.","journal-title":"J Sport Rehabil"},{"issue":"6","key":"1159_CR104","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1177\/1352458506073780","volume":"13","author":"OH Bjarnadottir","year":"2007","unstructured":"Bjarnadottir OH, et al. Multiple sclerosis and brief moderate exercise. A randomised study. Mult Scler. 2007;13(6):776\u201382.","journal-title":"Mult Scler"},{"issue":"2","key":"1159_CR105","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.apmr.2003.06.003","volume":"85","author":"LS DeBolt","year":"2004","unstructured":"DeBolt LS, McCubbin JA. The effects of home-based resistance exercise on balance, power, and mobility in adults with multiple sclerosis. Arch Phys Med Rehabil. 2004;85(2):290\u20137.","journal-title":"Arch Phys Med Rehabil"},{"issue":"6","key":"1159_CR106","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/PSY.0b013e31829b4525","volume":"75","author":"LA Pilutti","year":"2013","unstructured":"Pilutti LA, et al. Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis. Psychosom Med. 2013;75(6):575\u201380.","journal-title":"Psychosom Med"},{"issue":"10","key":"1159_CR107","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.apmr.2021.03.026","volume":"102","author":"L Taul-Madsen","year":"2021","unstructured":"Taul-Madsen L, et al. Is aerobic or resistance training the most effective exercise modality for improving lower extremity physical function and perceived fatigue in people with multiple sclerosis? A systematic review and meta-analysis. Arch Phys Med Rehabil. 2021;102(10):2032\u201348.","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"1159_CR108","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1177\/1352458520910360","volume":"26","author":"U Dalgas","year":"2020","unstructured":"Dalgas U, et al. Moving exercise research in multiple sclerosis forward (the MoXFo initiative): developing consensus statements for research. Mult Scler. 2020;26(11):1303\u20138.","journal-title":"Mult Scler"},{"issue":"6","key":"1159_CR109","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jpsychores.2014.03.014","volume":"76","author":"I Ensari","year":"2014","unstructured":"Ensari I, Motl RW, Pilutti LA. Exercise training improves depressive symptoms in people with multiple sclerosis: results of a meta-analysis. J Psychosom Res. 2014;76(6):465\u201371.","journal-title":"J Psychosom Res"},{"key":"1159_CR110","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/bs.apha.2017.05.003","volume":"80","author":"K Starowicz","year":"2017","unstructured":"Starowicz K, Finn DP. Cannabinoids and pain: sites and mechanisms of action. Adv Pharmacol. 2017;80:437\u201375.","journal-title":"Adv Pharmacol"},{"key":"1159_CR111","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/B978-0-444-63916-5.00004-5","volume":"159","author":"PA Forbes","year":"2018","unstructured":"Forbes PA, Chen A, Blouin JS. Sensorimotor control of standing balance. Handb Clin Neurol. 2018;159:61\u201383.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"1159_CR112","first-page":"80","volume":"37","author":"BL Riemann","year":"2002","unstructured":"Riemann BL, Lephart SM. The sensorimotor system, part II: the role of proprioception in motor control and functional joint stability. J Athl Train. 2002;37(1):80\u20134.","journal-title":"J Athl Train"},{"issue":"2","key":"1159_CR113","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08990220802131127","volume":"25","author":"MH Cameron","year":"2008","unstructured":"Cameron MH, et al. Imbalance in multiple sclerosis: a result of slowed spinal somatosensory conduction. Somatosens Mot Res. 2008;25(2):113\u201322.","journal-title":"Somatosens Mot Res"},{"key":"1159_CR114","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","volume":"9","author":"SB Claflin","year":"2018","unstructured":"Claflin SB, Broadley S, Taylor BV. The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses. Front Neurol. 2018;9:1150.","journal-title":"Front Neurol"},{"issue":"4","key":"1159_CR115","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.12203","volume":"275","author":"AH Cross","year":"2014","unstructured":"Cross AH, Naismith RT. Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med. 2014;275(4):350\u201363.","journal-title":"J Intern Med"},{"issue":"2","key":"1159_CR116","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","volume":"89","author":"DM Wingerchuk","year":"2014","unstructured":"Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225\u201340.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1159_CR117","first-page":"426","volume":"8","author":"SR Mehr","year":"2015","unstructured":"Mehr SR, Zimmerman MP. Reviewing the unmet needs of patients with multiple sclerosis. Am Health Drug Benefits. 2015;8(8):426\u201331.","journal-title":"Am Health Drug Benefits"},{"issue":"9","key":"1159_CR118","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrneurol.2012.136","volume":"8","author":"RW Motl","year":"2012","unstructured":"Motl RW, Pilutti LA. The benefits of exercise training in multiple sclerosis. Nat Rev Neurol. 2012;8(9):487\u201397.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1159_CR119","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/NPT.0000000000000087","volume":"39","author":"BM Sandroff","year":"2015","unstructured":"Sandroff BM, Klaren RE, Motl RW. Relationships among physical inactivity, deconditioning, and walking impairment in persons with multiple sclerosis. J Neurol Phys Ther. 2015;39(2):103\u201310.","journal-title":"J Neurol Phys Ther"},{"issue":"6","key":"1159_CR120","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2522\/ptj.20120178","volume":"93","author":"PK Padgett","year":"2013","unstructured":"Padgett PK, Kasser SL. Exercise for managing the symptoms of multiple sclerosis. Phys Ther. 2013;93(6):723\u20138.","journal-title":"Phys Ther"},{"issue":"Suppl 1","key":"1159_CR121","first-page":"S31","volume":"37","author":"AP Turner","year":"2020","unstructured":"Turner AP, Knowles LM. Behavioral interventions in multiple sclerosis. Fed Pract. 2020;37(Suppl 1):S31-s35.","journal-title":"Fed Pract"},{"issue":"7","key":"1159_CR122","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.apmr.2015.02.011","volume":"96","author":"M Pearson","year":"2015","unstructured":"Pearson M, Dieberg G, Smart N. Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil. 2015;96(7):1339-1348.e7.","journal-title":"Arch Phys Med Rehabil"},{"key":"1159_CR123","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cct.2017.07.016","volume":"61","author":"BM Sandroff","year":"2017","unstructured":"Sandroff BM, et al. Multimodal exercise training in multiple sclerosis: a randomized controlled trial in persons with substantial mobility disability. Contemp Clin Trials. 2017;61:39\u201347.","journal-title":"Contemp Clin Trials"},{"key":"1159_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.837710","volume":"13","author":"K Teraz","year":"2022","unstructured":"Teraz K, et al. Impact of motor-cognitive interventions on selected gait and balance outcomes in older adults: a systematic review and meta-analysis of randomized controlled trials. Front Psychol. 2022;13: 837710.","journal-title":"Front Psychol"},{"issue":"10","key":"1159_CR125","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1177\/15459683241273402","volume":"38","author":"A Wallin","year":"2024","unstructured":"Wallin A, et al. Effects of balance exercise interventions on balance-related performance in people with multiple sclerosis: a systematic review and a meta-analysis of randomized controlled trials. Neurorehabil Neural Rep. 2024;38(10):775\u201390.","journal-title":"Neurorehabil Neural Rep"},{"key":"1159_CR126","doi-asserted-by":"crossref","unstructured":"Zieli\u0144ska-Nowak E, et al. New strategies for rehabilitation and pharmacological treatment of fatigue syndrome in multiple sclerosis. J Clin Med. 2020;9(11):3592.","DOI":"10.3390\/jcm9113592"},{"issue":"4","key":"1159_CR127","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3988\/jcn.2011.7.4.184","volume":"7","author":"BI Han","year":"2011","unstructured":"Han BI, Song HS, Kim JS. Vestibular rehabilitation therapy: review of indications, mechanisms, and key exercises. J Clin Neurol. 2011;7(4):184\u201396.","journal-title":"J Clin Neurol"},{"issue":"1","key":"1159_CR128","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/13524585231215960","volume":"30","author":"CL Hugos","year":"2024","unstructured":"Hugos CL, et al. Stretching is not essential for managing MS spasticity: a randomized controlled trial. Mult Scler. 2024;30(1):89\u2013102.","journal-title":"Mult Scler"},{"key":"1159_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103167","volume":"55","author":"M Ganesan","year":"2021","unstructured":"Ganesan M, Skias D, Aruin AS. Enhancement of balance, and mobility in individuals with multiple sclerosis using visual cue guided multidirectional step training\u2014a pilot study. Mult Scler Relat Disord. 2021;55: 103167.","journal-title":"Mult Scler Relat Disord"},{"issue":"22","key":"1159_CR130","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1080\/09638288.2022.2138570","volume":"45","author":"S Monjezi","year":"2023","unstructured":"Monjezi S, et al. Perturbation-based balance training to improve postural responses and falls in people with multiple sclerosis: a randomized controlled trial. Disabil Rehabil. 2023;45(22):3649\u201355.","journal-title":"Disabil Rehabil"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01159-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01159-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01159-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:52:37Z","timestamp":1741971157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01159-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01159-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"15 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no funding for this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"R.W.M. generated the idea for the paper, and the idea was refined in conversations with T.B., A.A.J., and R.P. The literature search and analysis were conducted by A.A.J. and R.P. and overseen by R.W.M. and T.B. All authors wrote sections of the paper, and the sections were combined into the entire paper by A.A.J. and R.P. All authors critically revised and reviewed the entire paper and provided approval of the final version for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}